BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15155981)

  • 21. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
    Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
    Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.
    Pichyangkul S; Gettayacamin M; Miller RS; Lyon JA; Angov E; Tongtawe P; Ruble DL; Heppner DG; Kester KE; Ballou WR; Diggs CL; Voss G; Cohen JD; Walsh DS
    Vaccine; 2004 Sep; 22(29-30):3831-40. PubMed ID: 15364429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.
    Mettens P; Dubois PM; Demoitié MA; Bayat B; Donner MN; Bourguignon P; Stewart VA; Heppner DG; Garçon N; Cohen J
    Vaccine; 2008 Feb; 26(8):1072-82. PubMed ID: 18258343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
    Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
    Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.
    Brando C; Ware LA; Freyberger H; Kathcart A; Barbosa A; Cayphas S; Demoitie MA; Mettens P; Heppner DG; Lanar DE
    Infect Immun; 2007 Feb; 75(2):838-45. PubMed ID: 17101665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.
    Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Wellde BT; White K; Sun P; Schwenk R; Krzych U; Delchambre M; Voss G; Dubois MC; Gasser RA; Dowler MG; O'Brien M; Wittes J; Wirtz R; Cohen J; Ballou WR;
    Vaccine; 2007 Jul; 25(29):5359-66. PubMed ID: 17574311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
    Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
    Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RTS,S/AS02A for malaria.
    Bojang KA
    Expert Rev Vaccines; 2006 Oct; 5(5):611-5. PubMed ID: 17181435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
    Sacarlal J; Aide P; Aponte JJ; Renom M; Leach A; Mandomando I; Lievens M; Bassat Q; Lafuente S; Macete E; Vekemans J; Guinovart C; Sigaúque B; Sillman M; Milman J; Dubois MC; Demoitié MA; Thonnard J; Menéndez C; Ballou WR; Cohen J; Alonso PL
    J Infect Dis; 2009 Aug; 200(3):329-36. PubMed ID: 19569964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
    Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Krzych U; Delchambre M; Voss G; Dowler MG; Palensky J; Wittes J; Cohen J; Ballou WR;
    J Infect Dis; 2001 Feb; 183(4):640-7. PubMed ID: 11170991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
    Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
    Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
    Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
    Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
    Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
    Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
    Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
    Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
    Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
    J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.